Cheryl Cohen - NantKwest Director

Director

Ms. Cheryl L. Cohen is Director of the Company. She has served as president of CLC Consulting, a pharmaceutical and biotechnology consulting firm specializing in new product startup and commercialization, since 2008. Prior to CLC, Ms. Cohen served as chief commercial officer of Medivation, Inc., a publiclytraded biopharmaceutical company, from September 2011 until July 2014. From November 2007 to September 2008, she served as the vice president, strategic commercial group, of Health Care Systems, Inc., a Johnson Johnson company, and from October 1998 to November 2007, she worked at Janssen Biotech, Inc., a Johnson Johnson company, in a variety of senior sales roles including vice president, rheumatology franchise. Ms. Cohen has served on the board of Aerpio Pharmaceuticals, Inc., a pharmaceutical company, since 2018. Ms. Cohen also served on the board of Vital Therapies, Inc., a therapeutics company, from 2015 until 2019. Since 2015, Ms. Cohen has served on the board of Novus Therapeutics, Inc., a publiclytraded pharmaceutical company focused on the acquisition, development, and commercialization of ear, nose, and throat products. Ms. Cohen served on the board of Protein Sciences Corporationrationration, a privately held biopharmaceutical company specializing in vaccine development from October 2014 to August 2017, and she served on the board of Cytrx Corporationrationration, a publicly traded biopharmaceutical company specializing in oncology, from June 2015 through October 2016. Ms. Cohen began her career at Solvay Pharmaceuticals in a variety of sales positions since 2019.
Age 52
Tenure 5 years
Phone858 633-0300
Webwww.nantkwest.com
Cohen received her B.A. from Saint Joseph College.

NantKwest Management Efficiency

The company has Return on Asset (ROA) of (38.83) % which means that for every 100 dollars spent on asset, it generated a loss of $38.83. This is way below average. Likewise, it shows a return on total equity (ROE) of (77.61) %, which implies that it produced no returns to current stockholders. NantKwest's management efficiency ratios could be used to measure how well NantKwest manages its routine affairs as well as how well it operates its assets and liabilities.
The company reports 15.31 M of total liabilities with total debt to equity ratio (D/E) of 0.13, which may suggest the company is not taking enough advantage from financial leverage. NantKwest has a current ratio of 3.0, indicating that it is in good position to pay out its debt commitments in time. Debt can assist NantKwest until it has trouble settling it off, either with new capital or with free cash flow. So, NantKwest's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like NantKwest sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for NantKwest to invest in growth at high rates of return. When we think about NantKwest's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Glenn CorlettRocky Brands
73
Michael FinnRocky Brands
70
Ryan CottonCanada Goose Holdings
41
James ShennanStarbucks
73
Brenda MorrisBoot Barn Holdings
55
Andrea GuthrieShoe Carnival
45
Juan CerdaMeli Hotels International
N/A
Mark SchillerKontoor Brands
59
Lisa LaubeBoot Barn Holdings
58
Robert LynchKontoor Brands
44
Anne MacDonaldBoot Barn Holdings
65
Jerome KransdorfThe Cheesecake Factory
79
Jorgen KnudstorpStarbucks
49
Richard CarucciKontoor Brands
61
Joshua RamoStarbucks
48
Satya NadellaStarbucks
51
James SimmonsBoot Barn Holdings
60
Maria JaumeMeli Hotels International
N/A
Stephen GunnCanada Goose Holdings
65
William JordanRocky Brands
45
John DavisonCanada Goose Holdings
62
NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California. Nantkwest Inc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. NantKwest (NK) is traded on NASDAQ Exchange in USA and employs 160 people.

Management Performance

NantKwest Leadership Team

Elected by the shareholders, the NantKwest's board of directors comprises two types of representatives: NantKwest inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NantKwest. The board's role is to monitor NantKwest's management team and ensure that shareholders' interests are well served. NantKwest's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NantKwest's outside directors are responsible for providing unbiased perspectives on the board's policies.
Cheryl Cohen, Director
Richard Kusserow, Independent Director
Angela Wilson, CFO
Sonja Nelson, Chief Accounting Officer
Barry Simon, President CEO, Board Member
Michael Blaszyk, Independent Director
Frederick Driscoll, Independent Director
John Thomas, Independent Director
Robert Rosen, Director
Richard Tajak, Interim CFO
Patrick SoonShiong, Chairman of the Board, CEO
Henry Ji, Director
John Potts, Independent Director
Steven Gorlin, Vice Chairman of the Board

NantKwest Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NantKwest a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Other Consideration for investing in NantKwest Stock

If you are still planning to invest in NantKwest check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NantKwest's history and understand the potential risks before investing.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Insider Screener
Find insiders across different sectors to evaluate their impact on performance